Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €23.56 EUR
Change Today +0.019 / 0.08%
Volume 100.0
As of 3:35 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

mevis medical solutions ag (M3V) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/11/15 - €24.93
52 Week Low
10/16/14 - €12.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEVIS MEDICAL SOLUTIONS AG (M3V)

Related News

No related news articles were found.

mevis medical solutions ag (M3V) Related Businessweek News

No Related Businessweek News Found

mevis medical solutions ag (M3V) Details

MeVis Medical Solutions AG, together with its subsidiaries, develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms. Its clinical focuses include image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. This segment also offers image and risk analysis for planning liver surgery and tumor diagnostics in connection with clinical studies of pharmaceutical companies. The company has operations in the United States and Europe. MeVis Medical Solutions AG was founded in 1992 and is based in Bremen, Germany. As of March 24, 2015, MeVis Medical Solutions AG operates as a subsidiary of VMS Deutschland Holdings GmbH.

91 Employees
Last Reported Date: 08/12/15
Founded in 1992

mevis medical solutions ag (M3V) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €271.5K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €235.8K
Compensation as of Fiscal Year 2014.

mevis medical solutions ag (M3V) Key Developments

MeVis Medical Solutions AG Announces Earnings Results for the Second Quarter Ended June 30, 2015

MeVis Medical Solutions AG announced earnings results for the second quarter ended June 30, 2015. For the quarter, the company’s sales came to EUR 3,730,000 compared to EUR 3,234,000 a year ago and surpassing the first quarter of 2015 of EUR 3,408,000. At EUR 7,138,000, sales in the first half of the year increased considerably year on year to EUR 6,062,000. The growth in sales is entirely attributable to the US dollar exchange rate, which contributed EUR 1,145,000 to sales growth in the half year. Due to increased sales and despite the cessation of the capitalization of development expenses, the company a slight increase of the EBITDA (earnings before interest, taxes, depreciation and amortization) by 2 %, from EUR 2,605,000 to EUR 2,667,000. Net profit fell by EUR 459,000 to EUR 1,268,000, which is equivalent to undiluted earnings per share of EUR 0.72 compared to EUR 1.00 a year ago.

Mevis Medical Solutions AG Revises Earnings Guidance for the Year 2015

MeVis Medical Solutions AG revised earnings guidance for the year 2015. For the year 2015, revenues are expected to increase to between EUR 14.0 million and EUR 14.5 million compared to previous forecast stable at EUR 13.0 million and EUR 13.5 million. EBIT now a slight decrease over the previous year to EUR 3.0 million to EUR 3.5 million is forecasted compared to previous forecast EUR 2.0 million to EUR 2.5 million.

MeVis Medical Solutions AG Announces Changes in the Supervisory Board

MeVis Medical Solutions AG announced change in the Supervisory Board. Mr. Joerg Faessler and Mr. Glen Hilton, both in responsible executive positions at Varian Medical Systems, were elected as Supervisory Board members in the company's Annual General Meeting on June 9, 2015. Thus they replace the former Supervisory Board members Prof. Dr. Heinz-Otto Peitgen and Mr. Peter Kuhlmann-Lehmkuhle, who had resigned from their respective offices on April 10, 2015 effective as of the end of the Annual General Meeting on June 9, 2015. Dr. Jens Kruse will remain a member of the Supervisory Board. In the Supervisory Board Meeting held on June 10, 2015, Mr. Joerg Faessler was elected as Chairman of the Supervisory Board and Dr. Jens Kruse as Deputy Chairman.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
M3V:GR €23.56 EUR +0.019

M3V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for M3V.
View Industry Companies

Industry Analysis


Industry Average

Valuation M3V Industry Range
Price/Earnings 13.0x
Price/Sales 3.0x
Price/Book 1.3x
Price/Cash Flow 8.5x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEVIS MEDICAL SOLUTIONS AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at